• 1
    Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
  • 2
    Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999; 156: 16861696.
  • 3
    Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J. Clin. Psychiatry 2004; 65 (Suppl. 18): 3646.
  • 4
    Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008; 192: 406411.
  • 5
    American Diabetic Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596601.
  • 6
    U.S. Food & Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Patient Safety News: Show #28, June 2004.
  • 7
    Ministry of Health, Labour and Welfare. Diabetic ketoacidosis and coma due to hyperglycemia during olanzapine treatment. 2002. Available from URL: (last accessed 16 April 2002) (in Japanese).
  • 8
    Ministry of Health, Labour and Welfare. Diabetic ketoacidosis and coma due to hyperglycemia during quetiapine treatment. 2002. Available from URL: (last accessed 17 November 2002) (in Japanese).
  • 9
    Okumura Y, Misawa F, Nakabayashi T, Ito H. Pharmacotherapy of atypical antipsychotics and risk for diabetes in schizophrenia: a meta-analysis. Jpn. J. Clin. Psychopharmacol. 2010; 13: 317325 (in Japanese).
  • 10
    Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry 2006; 51: 492501.
  • 11
    Woo V, Harris SB, Houlden RL, Canadian Diabetes Association. Canadian diabetes association position paper: antipsychotic medications and associated risks of weight gain and diabetes. Can. J. Diabetes 2005; 29: 111112.
  • 12
    Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother. Psychosom. 2002; 71: 244254.
  • 13
    Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 2001; 62 (Suppl. 27): 1526.
  • 14
    Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med. J. Aust. 2004; 181: 544548.
  • 15
    Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J. Clin. Psychiatry 2001; 62 (Suppl. 27): 59.
  • 16
    Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J. Clin. Psychiatry 2001; 62 (Suppl. 23):3038.
  • 17
    Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286: 19451948.
  • 18
    Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 2004; 161: 13341349.
  • 19
    Murasaki M, Koyama T, Atsumi Y, Kadowaki T. Proposal of monitoring guidance for blood glucose in patients treated with second generation (atypical) antipsychotics. Jpn. J. Clin. Psychopharmacol. 2008; 11: 11391148 (in Japanese).
  • 20
    Seino Y, Nanjo K, Tajima N et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J. Japan Diab. Soc. 2010; 53: 450467 (in Japanese).
  • 21
    Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr. Res. 2010; 119: 145152.
  • 22
    Van Winkel R, De Hert M, Van Eyck D et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening method. J. Clin. Psychiatry 2006; 67: 14931500.
  • 23
    Grundy SM. Hyperglycemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 1998; 81 (Suppl. 4A): 18B25B.
  • 24
    Casey DE. Dyslipidemia and atypical antipsychotic drugs. J. Clin. Psychiatry 2004; 65 (Suppl. 18): 2735.
  • 25
    Sugawara N, Yasui-Furukori N, Sato Y et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr. Res. 2010; 123: 244250.
  • 26
    Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am. J. Psychiatry 2009; 166: 345353.